The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for Leqembi, which exceeded consensus estimates. The ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Verywell Health's content is for informational and educational purposes only. Our website is not intended to be a substitute ...

Research supporting the amyloid hypothesis—the idea that Alzheimer's is caused by a buildup of amyloid plaques in the ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...

The FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...